Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
Expert Committees
Advisory groups
Databases
Publications
All →
3 October 2025
WHO Drug Information - Volume 39, No. 3
The Third issue of volume 39 for 2025 includes:Consultation Documents: Cefiderocol sulfate tosilate (cefiderocoli sulfas tosilatum) Cefiderocol powder...
23 September 2025
Availability, price and affordability of health technologies for the management of diabetes
The WHO list of priority medical devices for management of cardiovascular diseases and diabetes, https://iris.who.int/handle/10665/341967, describes those...
5 September 2025
The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification...
The AWaRe classification is intended as a tool for monitoring antibiotic use, defining targets and monitoring the impact of stewardship policies and interventions...
5 September 2025
The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines for Children,...
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and...
Journal articles
WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines: Geneva, Switzerland, December 2019
npj Vaccines 5, 52 (2020)
WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71
Vaccine, Volume 38, Issue 32, 6 July 2020, Pages 4917-4923
Best Practices in Dengue Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention Boards
PLoS neglected tropical diseases vol. 4,11 e890. 16 Nov. 2010